Back to news

Aytu BioPharma Reports Fiscal 2027 First Quarter Operational and Financial Results

ACCESSWIRE•16/11/2026•16:15 ET
0

Key Highlights

  • ➤Rosemont to acquire Aytu for $2.70 per share in cash, approximately $56 million
  • ➤Q1 fiscal 2027 net revenue increased 6.9% to $14.8 million
  • ➤EXXUA revenue reached $4.9 million, up 24.5% sequentially
  • ➤Net loss was $3.9 million versus $2.0 million net income year over year
  • ➤ADHD Portfolio revenue fell to $7.7 million from $13.2 million

Expert Statements

Josh Disbrow, Chief Executive Officer of Aytu BioPharma

“Our first quarter performance was driven by growth in EXXUA, with net revenue increasing to $4.9 million and total prescriptions growing to 4,400 for the quarter, up approximately 33% sequentially from the June quarter.”

Josh Disbrow, Chief Executive Officer of Aytu BioPharma

“We look forward to continuing to support patients living with major depressive disorder.”

Josh Disbrow, Chief Executive Officer of Aytu BioPharma

“Today, we announced that Aytu has entered into a definitive agreement to be acquired by Rosemont for $2.70 per share in cash. This agreement with Rosemont reflects the work our team has done to build our CNS and pediatric portfolio and earn the trust of the patients and healthcare providers we serve. We see a strong strategic fit between our portfolio and Rosemont's experience developing and commercializing specialty medicines. Importantly, we believe the transaction delivers compelling value to our shareholders and that, together, we can help more patients get the treatment they need.”

DENVER, CO / ACCESS Newswire / November 16, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced operational and financial results for the fiscal 2027 first quarter ended September 30, 2026.

Q1 Fiscal 2027 Highlights * Net revenue increased 6.9% to $14.8 million versus $13.9 million in Q1 fiscal 2026. * EXXUA net revenue was $4.9 million, up 24.5% from $3.9 million in Q4 fiscal 2026. Total prescriptions increased 32.5% sequentially to 4,400 for the quarter, including a monthly high of approximately 1,650 in September 2026. * ADHD Portfolio net revenue was $7.7 million versus $13.2 million in Q1 fiscal 2026, primarily reflecting reduced promotional emphasis as commercial resources shifted toward EXXUA and generic competition. * Pediatric Portfolio net revenue was $2.2 million versus $0.7 million in Q1 fiscal 2026, primarily reflecting improved payer mix and lower returns. * Net loss was ($3.9) million, including a $0.3 million derivative warrant liabilities gain, compared to net income of $2.0 million in Q1 fiscal 2026, which included a $3.8 million derivative warrant liabilities gain. * Adjusted EBITDA was ($2.6) million compared to ($0.6) million in Q1 fiscal 2026, primarily reflecting continued EXXUA commercialization investments. * Cash and cash equivalents were $25.5 million at September 30, 2026, compared to $26.3 million at June 30, 2026. Pending Merger

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in